Evidence map›Paper›PMID 42818163›Full record

ArticlemedRxiv : the preprint server for health sciences2026

Targeting Polθ Helicase with RP-3467: Preclinical Validation and Clinical Response in a g

Ezra Y Rosen, Marie-Claude Mathieu, Gino B Ferraro, Philippe Mochirian, Claude Godbout, Hugo Poirier, Sara Fournier, Danielle Henry, Hyeyeon Kim, Robert Papp and 22 more

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Ezra Y RosenDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Marie-Claude MathieuRepare Therapeutics Inc., Saint Laurent, Quebec, Canada.
Gino B FerraroRepare Therapeutics Inc., Saint Laurent, Quebec, Canada.
Philippe MochirianRepare Therapeutics Inc., Saint Laurent, Quebec, Canada.
Claude GodboutRepare Therapeutics Inc., Saint Laurent, Quebec, Canada.
Hugo PoirierRepare Therapeutics Inc., Saint Laurent, Quebec, Canada.
Sara FournierRepare Therapeutics Inc., Saint Laurent, Quebec, Canada.
Danielle HenryRepare Therapeutics Inc., Saint Laurent, Quebec, Canada.
Hyeyeon KimRepare Therapeutics Inc., Saint Laurent, Quebec, Canada.
Robert PappRepare Therapeutics Inc., Saint Laurent, Quebec, Canada.
Shou Yun YinRepare Therapeutics Inc., Saint Laurent, Quebec, Canada.
Marie-Eve LeclaireRepare Therapeutics Inc., Saint Laurent, Quebec, Canada.
Robert HouleRepare Therapeutics Inc., Saint Laurent, Quebec, Canada.
Parham NejadRepare Therapeutics Inc., Saint Laurent, Quebec, Canada.
Joseph D SchonhoftRepare Therapeutics Inc., Saint Laurent, Quebec, Canada.
Karl E ZahnRepare Therapeutics Inc., Saint Laurent, Quebec, Canada.
W Cameron BlackRepare Therapeutics Inc., Saint Laurent, Quebec, Canada.
Michel GallantRepare Therapeutics Inc., Saint Laurent, Quebec, Canada.
Insil KimRepare Therapeutics Inc., Cambridge, MA, USA.
Danielle UlanetRepare Therapeutics Inc., Cambridge, MA, USA.
Paul BascianoRepare Therapeutics Inc., Cambridge, MA, USA.
Artur VelosoRepare Therapeutics Inc., Cambridge, MA, USA.
Victoria RimkunasRepare Therapeutics Inc., Cambridge, MA, USA.
Timothy A YapInvestigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Robin GuoDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nicholas MaiDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Maria KoehlerRepare Therapeutics Inc., Cambridge, MA, USA.
Michael ZindaRepare Therapeutics Inc., Cambridge, MA, USA.
Anne RoulstonRepare Therapeutics Inc., Saint Laurent, Quebec, Canada.
Michal ZimmermannRepare Therapeutics Inc., Saint Laurent, Quebec, Canada.
Stephen J MorrisRepare Therapeutics Inc., Saint Laurent, Quebec, Canada.
Agnel SfeirMolecular Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-1633-8535

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Targeting Polθ to Overcome PARP Inhibitor Resistance in Homologous Recombination Deficient Breast CancerP50CA247749 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Simon N. Powell · 2020 to 2026
$16.3M
The University of Texas MD Anderson Cancer Center SPORE in Ovarian CancerP50CA281701 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ROBERT C BAST, ANIL K SOOD · 2023 to 2026
$11.5M
Investigating PolQ-mediated alternative NHEJ in breast cancerR01CA229161 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SFEIR, AGNEL · 2019 to 2023
$2.1M
Transcriptomic mechanisms underlying the immune modulating function and therapeutic efficacy of PARP inhibitorsR01CA255074 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI YAP, TIMOTHY ANTHONY · 2021 to 2025
$1.8M
Investigating the role of Microhomology-Mediated End-Joining (MMEJ) in Mitosis and its impact on drug resistanceR01CA294696 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Agnel Sfeir · 2025 to 2026
$1.2M
NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA247749NCI NIH HHS P50 CA281701NCI NIH HHS R01 CA229161NCI NIH HHS R01 CA255074NCI NIH HHS R01 CA294696
6 · The paper itself

Abstract

Homologous recombination (HR) deficiency underlies a range of cancers, and PARP inhibitors (PARPi) targeting this vulnerability have demonstrated clinical efficacy in

Indexed as

BRCA1BRCA2DNA double-strand breaks (DSBs)homologous recombination deficient (HRD)Microhomology-mediated end-joining (MMEJ)mitotic repairovarian cancerpolymerase theta (Polθ)

Identifiers

PMID42818163
PMCPMC13622306

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.